Sinclair Rodney, Sicinska Justyna, Bokhari Laita, Kasprzak Michal
Sinclair Dermatology, Melbourne, VIC, Australia.
TrichoLAB AB, Warsaw, Poland.
Clin Exp Dermatol. 2025 Jun 25;50(7):1362-1365. doi: 10.1093/ced/llaf012.
The histological hallmark of male androgenetic alopecia (MAGA) is the transformation of terminal follicles into miniaturized secondary vellus follicles. As the volume of the dermal papilla determines the size of the hair bulb and hair fibre diameter, any treatment-induced increase in fibre diameter could be used as a proxy for reversal of hair follicle miniaturization. Although clinical trials with minoxidil topical solution in MAGA do not demonstrate increased fibre diameter, vellus-to-terminal reconversion is shown in a humanized mouse model treated with minoxidil.
To investigate whether low-dose sublingual minoxidil (SLM) increases hair fibre diameter in MAGA.
Serial tattoo-localized phototrichograms were analysed using hair-to-hair (H2H) matching software in 33 patients with MAGA who participated in a 24-week randomized, double-blinded, placebo-controlled, clinical trial with SLM 0.45 mg once daily. Additional data were obtained from 12 participants who had used a placebo and then rolled into a 24-week, open-label, extension study with either once-daily 1.35 mg or 4.05 mg SLM. TrichoLAB (Warsaw, Masovian, Poland) H2H analysis uniquely identified individual hairs and measured hair fibre diameter at baseline and 24 weeks.
After 24 weeks, fibre diameter decreased by 2 µm (SD 1) in men receiving placebo. The decrease was most marked in intermediate diameter fibres with a baseline diameter of 40-60 µm. Among men receiving SLM 0.45 mg, 1.35 mg and 4.05 mg, the mean increase in fibre diameter was -2 µm (SD 1 µm), 3 µm (SD 1 µm) and 6 µm (SD 1 µm), respectively. Intermediate-thickness fibres increased the most. H2H matching demonstrated increased diameter in individual fibres.
The effect of SLM on mean fibre diameter was dose dependent. SLM 1.35 mg and 4.05 mg, but not 0.45 mg, significantly increased mean fibre diameter in MAGA (P < 0.05). The diameter increased most in the intermediate and thickest hairs. This increase in fibre diameter infers reversal of follicle miniaturization in MAGA and is consistent with the observation of vellus-to-terminal reconversion shown in a humanized mouse model treated with minoxidil.
男性雄激素性脱发(MAGA)的组织学特征是终毛毛囊转变为小型化的次级毳毛毛囊。由于真皮乳头的体积决定毛球大小和毛发纤维直径,任何治疗引起的纤维直径增加都可作为毛囊小型化逆转的替代指标。尽管米诺地尔局部溶液治疗MAGA的临床试验未显示纤维直径增加,但在米诺地尔治疗的人源化小鼠模型中显示了毳毛向终毛的再转化。
研究低剂量舌下含服米诺地尔(SLM)是否能增加MAGA患者的毛发纤维直径。
使用毛发对毛发(H2H)匹配软件对33例MAGA患者的连续纹身定位毛发照片进行分析,这些患者参与了一项为期24周的随机、双盲、安慰剂对照临床试验,每天一次服用0.45 mg SLM。另外从12名使用过安慰剂的参与者处获得数据,然后纳入一项为期24周的开放标签扩展研究,分别每日一次服用1.35 mg或4.05 mg SLM。TrichoLAB(波兰马佐夫舍省华沙)的H2H分析能够唯一识别个体毛发,并在基线和24周时测量毛发纤维直径。
24周后,接受安慰剂的男性纤维直径减少了2 µm(标准差1)。这种减少在基线直径为40 - 60 µm的中等直径纤维中最为明显。在接受0.45 mg、1.35 mg和4.05 mg SLM的男性中,纤维直径的平均增加分别为 -2 µm(标准差1 µm)、3 µm(标准差1 µm)和6 µm(标准差1 µm)。中等厚度的纤维增加最多。H2H匹配显示个体纤维直径增加。
SLM对平均纤维直径的影响呈剂量依赖性。1.35 mg和4.05 mg的SLM,但不是0.45 mg,能显著增加MAGA患者的平均纤维直径(P < 0.05)。在中等和最粗的毛发中直径增加最多。这种纤维直径的增加意味着MAGA中毛囊小型化的逆转,并且与米诺地尔治疗的人源化小鼠模型中显示的毳毛向终毛再转化的观察结果一致。